Ionis Beats Q1 Expectations, Raises 2026 Revenue Outlook on Strong Launches
Ionis Pharmaceuticals posted a robust first‑quarter 2026, with total revenue of $246 million and a GAAP operating loss that narrowed to $118 million. The company lifted its full‑year revenue guidance to $875‑$900 million, driven by rapid uptake of its own medicines and a surge in milestone payments, while reaffirming its cash‑flow‑breakeven target for 2028.
Quarter at a glance
Ionis delivered $246 million in revenue for Q1 2026, a 42% year‑over‑year increase, and trimmed its non‑GAAP operating loss to $75 million from $115 million a year ago. The market reacted positively, with the stock up 0.75% on the day of the filing, even as broader indices slipped. The beat was anchored by two themes: the accelerating commercial traction of its wholly‑owned products—TRYNGOLZA (olezarsen) and DAWNZERA (donidalorsen)—and an unprecedented influx of partnership‑related milestone cash.
Wholly owned medicines: the new growth engine
TRYNGOLZA generated $27 million in net U.S. sales, up from $6 million a year earlier, reflecting a 350% YoY surge as clinicians adopt the drug for familial chylomicronemia syndrome. DAWNZERA posted $16 million, a 125% jump versus Q4 2025, buoyed by a European launch led by Otsuka. Management highlighted that these products now contribute a larger slice of commercial revenue, reducing reliance on royalty streams. The pipeline is poised for two more independent launches this year: an sHTG indication for olezarsen (FDA priority review, PDUFA June 30) and zilganersen for Alexander disease (FDA priority review, PDUFA September 22). Both are expected to add $100‑$110 million and $110‑$120 million, respectively, to full‑year product sales, according to the updated guidance.
Partnered medicines: steady royalty engine
Royalty revenue slipped modestly to $58 million from $64 million a year ago, primarily because SPINRAZA’s $44 million and WAINUA’s $11 million royalties were offset by a slight dip in the underlying sales mix. SPINRAZA’s global sales of $374 million and WAINUA’s $51 million remain strong, underscoring the durability of Ionis’s partnership model. The company also announced a breakthrough: bepirovirsen met its primary endpoint in Phase 3 chronic hepatitis B trials, achieving a functional cure rate that earned FDA priority‑review status (PDUFA Oct 26) and Breakthrough Therapy designation. While bepirovirsen will not contribute to Q1 revenue, its upcoming approval could become a significant future royalty source.
Milestone and collaborative revenue: a cash windfall
R&D revenue exploded to $138 million, driven by $95 million in milestone payments and $120 million in collaborative agreement revenue. These inflows reflect the company’s deepening relationships with partners such as Alnylam, Roche, and Takeda, and they helped offset the higher commercialization spend associated with the new launches. The cash balance remains robust at $1.9 billion, even after deploying $633 million to retire 0% convertible notes.
Margin dynamics and expense discipline
GAAP operating loss narrowed to $118 million, while non‑GAAP loss fell to $75 million, indicating that the company is managing its cost base as launch activities ramp. Commercial expenses rose modestly to support TRYNGOLZA and DAWNZERA, but R&D spend stayed in line with historical levels, suggesting disciplined allocation of resources toward high‑impact programs.
Guidance upgrade and cash‑flow outlook
Ionis lifted its full‑year revenue outlook to $875‑$900 million (up from $800‑$825 million) and narrowed the non‑GAAP operating loss range to $425‑$475 million. The company also reaffirmed its goal of achieving cash‑flow breakeven by 2028, a target now supported by a stronger near‑term revenue trajectory and a deep cash runway exceeding $1.6 billion.
What investors should watch
- Regulatory milestones: FDA decisions on olezarsen (sHTG) and zilganersen will be pivotal in Q3‑Q4. A positive PDUFA outcome could accelerate revenue beyond the guidance range.
- Bepirovirsen rollout: If the Phase 3 data translate into approval, royalty streams from a chronic hepatitis B cure could materially boost long‑term cash flow.
- Partner pipeline health: Continued milestone deliveries from existing collaborations will be essential to fund commercialization while the company scales its own brands.
Overall, Ionis turned a traditionally loss‑heavy biotech into a revenue‑accelerating platform, leveraging both its own product launches and a thriving partnership ecosystem. The upgraded outlook and disciplined cash management position the company well for a pivotal 2026.
Financial Details
| Forward Guidance | |
| Revenue Guidance | Full Year 2026 Total Revenue $875‑$900 million (previous guidance $800‑$825 million); TRYNGOLZA product sales, net $100‑$110 million; DAWNZERA product sales, net $110‑$120 million |
| Other Guidance | Non‑GAAP Operating loss $425‑$475 million (previous $500‑$550 million); Cash, cash equivalents and short‑term investments > $1.6 billion; Goal to achieve cash‑flow breakeven in 2028 |
| Commentary | Management expects continued revenue acceleration from the launch of olezarsen in severe hypertriglyceridemia and zilganersen in Alexander disease, strong R&D milestone inflows, and positive data f... |
| Segment Highlights | ['Wholly Owned Medicines – TRYNGOLZA net sales $27\u202fM (up from $6\u202fM YoY); DAWNZERA net sales $16\u202fM (125% increase QoQ); olezarsen sNDA accepted for Priority Review for sHTG; zilganersen NDA accepted for Priority Review for Alexander disease.', 'Partnered Medicines – SPINRAZA generated $374\u202fM in global sales and $44\u202fM in royalties; WAINUA generated $51\u202fM in global sales and $11\u202fM in royalties; bepirovirsen achieved primary endpoint in Phase\u202f3 CHB and received FDA Priority Review.', 'Research & Development Revenue – $138\u202fM total, comprising $120\u202fM collaborative agreement revenue and $18\u202fM WAINUA joint development revenue, reflecting $95\u202fM in milestone payments.', 'Commercial Revenue – Total $108\u202fM, a 42% YoY increase, driven by product sales and royalty income.', 'Operating Expenses – GAAP operating loss $118\u202fM; non‑GAAP operating loss $75\u202fM, reflecting investments in commercialization of TRYNGOLZA, DAWNZERA, and launch preparations for olezarsen and zilganersen.'] |
| Key Metrics | |
| Cash and Short Term Investments | $1.9 billion |
| Escrow Deposit Used for Convertible Notes | $633 million |
| Total Revenue Q1 2026 | $246 million |
| Total Commercial Revenue Q1 2026 | $108 million |
| Total R&D Revenue Q1 2026 | $138 million |
| TRYNGOLZA Net Sales Q1 2026 | $27 million |
| DAWNZERA Net Sales Q1 2026 | $16 million |
| SPINRAZA Global Sales Q1 2026 | $374 million |
| WAINUA Global Sales Q1 2026 | $51 million |
| Bepirovirsen Phase3 Primary Endpoint | Achieved functional cure rate in CHB |
| Olezarsen sHTG PDUFA | June 30, 2026 |
| Zilganersen AxD PDUFA | September 22, 2026 |
| Bepirovirsen CHB PDUFA | October 26, 2026 |
Key Takeaways
- Q1 2026 revenue rose 42% YoY to $246 million, with GAAP operating loss narrowing to $118 million.
- TRYNGOLZA and DAWNZERA sales surged to $27 million and $16 million respectively, underscoring growing commercial traction of wholly owned medicines.
- R&D revenue jumped to $138 million, driven by $95 million in milestone payments and $120 million in collaborative agreement revenue.
- Full‑year 2026 revenue guidance raised to $875‑$900 million; non‑GAAP operating loss narrowed to $425‑$475 million.
- Cash and short‑term investments stand at $1.9 billion after settling $633 million of convertible notes.
- Regulatory milestones ahead: olezarsen (sHTG) PDUFA June 30, zilganersen PDUFA September 22, bepirovirsen PDUFA October 26.
- Management reaffirmed a cash‑flow breakeven target for 2028, supported by stronger launch pipeline and robust partnership cash flows.